DIR Return Create A Forum - Home
       ---------------------------------------------------------
       panflustats
  HTML https://panflustats.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: influenza
       *****************************************************
       #Post#: 3--------------------------------------------------
       new flu drugs
   DIR By: gsgs
       Date: July 19, 2017, 4:12 am
       ---------------------------------------------------------
       Nitazoxanide
       favipiravir
       fludase
       JNJ63623872 (formerly known as VX-787)
       S-033188
       Results from a phase IIb/III human clinical trial demonstrated
       that 600 mg
       NTZ twice daily (started within 48 hours of symptom onset)
       reduced symptom
       duration by 36 hours.
       In mice receiving the multiple dose regimen, there was a
       significant decrease
       in viral shedding and viral load up to 5 days from the
       commencement of treatment.[39]
       300 mg/kg dose of favipiravir=T705 resulted in nearly 100%
       survival rate in mice infected
       with H5N1, even when treatment was started 72 hours
       post-infection, compared
       to mice given a 50 mg/kg dosage of oseltamivir which had a 50%
       survival rate.[51]
       results from human trials are not publicly available concerning
       the safety or efficacy of the drug
       Administration of JNJ63623872 in mice up to 96 hours
       post-infection resulted in 100% survival and
       was superior to oseltamivir treatment in which 100% survival was
       only observed when
       mice were dosed up to 24 hours post-infection.[46]
       The JNJ63623872 treatment group had a quicker resolution of
       influenza-like symptoms
       (1.9 days) compared to the placebo group (3.7 days).[61]
       S-033188 had significant reductions in time to alleviation of
       symptoms and reduced
       virus titres at 24 and 48 hours post-treatment compared to
       placebo.[62]
       phase III clinical trial (NCT02949011) since Dec.2016
  HTML http://onlinelibrary.wiley.com/doi/10.1111/irv.12446/full
       *****************************************************
       Page 1 of 1